VIS-410
Based on 1 Customer Validation
VIS-410 is an antibody inhibitor targeting the stem region of hemagglutinin (HA). VIS-410 inhibits influenza virus replication by blocking HA-mediated membrane fusion. VIS-410 exhibits broad-spectrum neutralization against influenza A viruses with group 1 and group 2 hemagglutinins, including subtypes such as H1N1, H3N2, H5N1, and H7N9 (H5N1 IC50 = 1.5 μg/mL). VIS-410 is applicable to research related to influenza A virus infection.
For research use only. We do not sell to patients.
- Purity: 99%
- CAS No.: 2043950-09-8
- Molecular Weight:149.157 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Virus
influenza A virus hemagglutinin HA
VIS-410 potently inhibits replication of multiple influenza A virus strains (including H3N2 and H5N1) in MDCK cells, with IC50 values ranging from 0.3-11 µg/mL, by blocking HA-mediated membrane fusion[2].
VIS-410 exhibits an IC50 of 1.5 μg/mL against Duck/MN/1525/81 H5N1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
VIS-410 confers significant survival benefit in mice infected with H3N2 influenza A virus[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2043950-09-8
-
Appearance Liquid
-
Molecular Weight 149.157 kDa
-
Color Colorless to light yellow
-
SMILES
[VIS-410]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Koszalka P, et al. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11(3):240-246. [Content Brief]
[2]. Zeng LY, et al. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs. 2017;26(1):63-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)